Innovative Drug Delivery
Innovative Drug Delivery Technologies for Safer Medications
Research, development and commercialization of technologies and products intended to address safe use of medications.
Acura Pharmaceuticals, Inc. is an innovative specialty pharmaceutical company that researches, develops and seeks to commercialize technologies and products intended to address safe use of medications.
Our Technology Platforms
Three proprietary platforms addressing the most critical challenges in medication safety and abuse deterrence.
LIMITX™ Technology
Intended to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested.
Lead product: LTX-03 (hydrocodone bitartrate and acetaminophen). U.S. commercialization rights licensed to Abuse Deterrent Pharmaceuticals LLC.
AVERSION® Technology
Intended to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection.
Licensed to Zyla Life Sciences for OXAYDO® Tablets — the first approved immediate-release oxycodone product in the U.S. with abuse deterrent labeling (5mg and 7.5mg, FDA approved).
IMPEDE® Technology
Directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.
Used in Nexafed® (30mg pseudoephedrine HCl) and Nexafed® Sinus Pressure + Pain Tablets. Licensed to MainPointe Pharmaceuticals LLC for U.S. and Canada.
Pipeline & Products
Explore our full product pipeline, approved products, and products currently under development across all three platform technologies.
Partnering for a Safer Future
Acura actively seeks licensing and co-development partnerships for its proprietary technology platforms. Contact our business development team to explore opportunities.
Contact Business Development